Bowmans advised NATCO Pharma Limited on strategic acquisition of stake in Adcock Ingram Holdings
Bowmans advised NATCO Pharma Limited, a leading Indian pharmaceutical company listed on the Bombay Stock Exchange and National Stock Exchange of India, on its proposed acquisition of a significant minority equity stake (approximately 35.8%) in JSE-listed Adcock Ingram Holdings Limited for approximately USD 226 million. If successful, the transaction would result in the delisting of Adcock Ingram.
NATCO Pharma, with a market capitalization of about USD 2 billion, is a global leader in niche pharmaceutical products with a presence in over 50 countries. The company develops, manufactures, and markets specialty pharmaceuticals across various therapeutic segments in international markets, most notably India and the United States.
This landmark deal showcases Bowmans’ market-leading expertise in advising on high-value, transformative public deals in the pharmaceutical and FMCG sectors, especially those involving complex cross-border regulatory frameworks and multi-party stakeholder engagements. It further demonstrates the firm’s commitment to supporting strategic transactions that drive innovation and investment across the African continent.
“This deal is a testament to our team’s ability to advise on complex, high-stakes public transactions involving cross-border dynamics and multiple stakeholders. We are proud to support strategic investments that unlock growth across Africa.” — Ezra Davids, Chairman and Senior Partner at Bowmans
The Bowmans team advising on the transaction was led by Ezra Davids (Chairman and Senior Partner) and Ryan Wessels (Partner, Corporate/M&A), with support from Shmuel Moch, Judd Lurie, Lenja Dahms-Jansen, Jason Wilkinson, Cayley Lovatt, and other specialist team members.
If you have a news or deal publication or would like to collaborate on content, columns, or article publications, connect with the Legal Era News Network Team and email us at [email protected] or call us on +91 8879634922.